The debate proposed that Aβ-induced tau missorting creates self-sustaining toxicity, but didn't resolve whether this state is truly Aβ-independent once established. This is critical for understanding why anti-Aβ therapies fail and whether tau-targeting must follow specific temporal windows.
Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974_20260416-134419 (Analysis: SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974)
Aβ drives tau into dendritic spines, where tau binds Fyn and stabilizes a PSD95-NMDAR-associated excitotoxic scaffold. Once assembled, this complex may persist after Aβ clearance and maintain calcium dysregulation, hyperexcitability, and synaptic degeneration.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["MAPT Primary Target"]
B["Biological Process 1 Mechanistic Step A"]
C["Biological Process 2 Mechanistic Step B"]
D["Output Phenotype Disease Effect"]
A --> B
B --> C
C --> D
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMIDValidation: 0%3 supporting / 2 opposing
✓For(3)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
MECH 5CLIN 0GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Dendritic tau mediates Aβ toxicity via Fyn-depende…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-25 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Title: Fyn-anchored dendritic tau becomes self-sustaining after transient Aβ exposure
Mechanism: Aβ oligomers drive tau missorting from axon to dendritic spines, where tau binds FYN and stabilizes an NMDA receptor-associated excitotoxic signaling complex. Once established, this tau-Fyn-PSD95/NMDAR scaffold may persist without continued Aβ, maintaining calcium dysregulation, spine loss, and downstream degeneration.
Target gene/protein/pathway:MAPT (tau), FYN, PSD95/DLG4, NMDAR/SRC-family signalingSupporting evidence: Strong prior literature links dendritic tau
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Below the central skeptical point applies to all seven: current literature strongly supports that Aβ can induce dendritic/somatodendritic tau missorting and synaptic toxicity, but it does not cleanly establish that the state becomes truly Aβ-independent after complete Aβ removal. Most cited evidence is either acute Aβ exposure, constitutive transgenic overexpression, or end-stage human tissue, which cannot separate “self-sustaining tau pathology” from “residual upstream injury,” incomplete Aβ clearance, or generic degeneration.
**Fyn-anchored dendritic tau self-sustains after transient
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Most investable survivors are `6 > 4 > 1 > 2`. I would not spend serious translational budget yet on `7`, and I would treat `3` and `5` as modifier mechanisms rather than lead programs.
| Rank | Hypothesis | Druggability | Biomarkers | Best model systems | Safety / translational risk | Realistic path | |---|---|---|---|---|---|---| | 1 | `6` Tau missorting transitions into autonomous tau seeding | High, relative to others. Clear intervention classes: anti-tau antibodies, seed-blocking biologics, ASOs, uptake blockers. | CSF/plasma p-tau217, p-tau181, MTBR-tau, tau seeding assays, tau PET, syn
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"Tau missorting transitions into an autonomous tau-seeding state after transient Aβ exposure","description":"Transient Aβ exposure induces dendritic tau missorting that then converts into a locally self-propagating tau oligomer/seeding program. After verified Aβ clearance, continued degeneration is driven by tau seed formation, templated misfolding, and trans-synaptic spread rather than by ongoing amyloid signaling.","target_gene":"MAPT","dimension_scores":{"evidence_strength":0.78,"novelty":0.72,"feasibility":0.83,"therapeutic_potential":0.84,"mechanistic_plausi
IF wild‑type mice receive a single intracerebroventricular injection of Aβ1‑42 oligomers (300 pmol) followed by a 7‑day Aβ‑free period, THEN the amount of Fyn‑tau‑PSD95‑NMDAR complex recovered from synaptoneurosomes will remain at least 2‑fold higher than in vehicle‑treated controls, AND hippocampal intracellular calcium baseline will stay elevated by ≥30 %, both measured at day 7.
pendingconf: 0.65
Expected outcome: 2‑fold increase in co‑immunoprecipitated Fyn/tau/PSD95/GRIN2B and a ≥30 % rise in basal calcium fluorescence (GCaMP6f) in CA1 pyramidal neurons.
Falsified by: Complex abundance returns to ≤1.2‑fold of control AND calcium fluorescence is unchanged (<10 % difference), indicating no persistence.
Method: Adult C57BL/6 mice (n≥10 per group) injected icv with Aβ1‑42 oligomers; 7‑day washout; synaptoneurosome preparation for Co‑IP; in‑vivo calcium imaging via AAV‑GCaMP6f.
IF human iPSC‑derived cortical neurons are exposed to 200 nM Aβ1‑42 oligomers for 48 h, THEN after a 96‑h Aβ‑free interval the tau Y18 phosphorylation (Fyn site) co‑localized with PSD95 will stay >1.5‑fold above baseline, AND miniature excitatory postsynaptic current (mEPSC) frequency will remain reduced by ≥40 % compared to untreated cultures.
pendingconf: 0.60
Expected outcome: ≥1.5‑fold increase in PLA puncta for pTau(Y18)–PSD95 and ≥40 % decrease in mEPSC frequency.
Falsified by: pTau(Y18)–PSD95 PLA signal returns to ≤1.2‑fold baseline OR mEPSC frequency is unchanged (<15 % reduction), indicating no persistent signaling.
Method: iPSC‑derived cortical neurons (n≥6 differentiation batches); 48 h 200 nM Aβ1‑42 treatment; 96 h washout; PLA for pTau(Y18)–PSD95; whole‑cell patch‑clamp recordings of mEPSCs.